Hadewych ter Hofstede

Dr. Hadewych ter Hofstede

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ABAnneleen Berende
Anneleen Berende
HHHadewych ter Hofstede
Hadewych ter Hofstede
ADA Rogier T Donders
A Rogier T Donders
HMHenriët van Middendorp
Henriët van Middendorp
Roy P. C. KesselsRoy P. C. Kessels
Roy P. C. Kessels
BKBart Jan Kullberg
Bart Jan Kullberg
Lyme borreliosis, a potentially severe tick-borne infection caused by Borrelia burgdorferi, can cause multi-system inflammatory disease. The incidence has been increasing, as has the number of patients with persistent symptoms attributed to Borrelia. These symptoms, also referred to as post-Lyme disease syndrome, may follow an erythema migrans or other Lyme manifestations, and include pain, fatigue, and cognitive disturbances. The optimal duration of treatment for these symptoms is a subject of controversy. The PLEASE study is designed to determine whether prolonged antibiotic treatment leads to better patient outcome than standard treatment. The PLEASE study is a double-blind, randomized, placebo-controlled trial. Based on power analysis and compensating for possible loss to follow-up, a minimum of 255 patients with borreliosis-attributed persistent symptoms are included. These symptoms are either (a) temporally related to an erythema migrans or otherwise proven symptomatic borreliosis, or (b) accompanied by a positive B. burgdorferi IgG or IgM immunoblot. All patients receive open-label ceftriaxone for two weeks. Patients are then randomized (ratio 1:1:1) to blinded oral follow-up treatment for 12 weeks with (I) doxycycline, (II) clarithromycin combined with hydroxychloroquine, or (III) placebo. The primary outcome is the physical component summary score (PCS) of the RAND-36 Health Status Inventory (RAND SF-36) at week 14. Secondary outcomes include physical and mental aspects of health-related quality of life (assessed by the subscales of the RAND SF-36), fatigue, neuropsychological evaluation, physical activity, and cost-effectiveness. This article describes the background and design issues of the PLEASE study protocol. The results of this study may provide evidence for prescribing or withholding prolonged antibiotic treatment. ClinicalTrials.gov: NCT01207739, Netherlands Trial Register: NTR2469

6 May 2023 in Life
Verified
Journal Article
Open access
PDF file
FSFoekje Francina Stelma
Foekje Francina Stelma
ABAnneleen Berende
Anneleen Berende
HHHadewych ter Hofstede
Hadewych ter Hofstede
HVHedwig D. Vrijmoeth
Hedwig D. Vrijmoeth
FVFidel Vos
Fidel Vos
BKBart Jan Kullberg
Bart Jan Kullberg
Objective: The diagnosis of Lyme borreliosis is based on two-tier testing using an ELISA and Western blot. About 5–10% of patients report persistent symptoms of unknown etiology after treatment, resulting in substantial difficulties in further diagnostic workup. This paper presents a study aimed at determining whether serology can differentiate between patients with persistent symptoms attributed to Lyme and other patients with Lyme borreliosis. Methods: A retrospective cohort study included 162 samples from four subgroups: patients with persistent symptoms of Lyme (PSL), early Lyme borreliosis with erythema migrans (EM), patients tested in a general practitioner setting (GP), and healthy controls (HC). ELISA, Western blots, and multiplex assays from different manufacturers were used to determine inter-test variations in PSL and to compare reactivity against Borrelia-specific antigens among the groups. Results: In comparing the IgG and IgM reactivity by Western blot, IgG was more often positive in the PSL group than in the GP group. The individual antigen reactivity was similar between the PSL and EM or GP groups. Inter-test agreement among the manufacturers was variable, and agreement was higher for IgG testing compared to IgM. Conclusions: Serological testing is unable to define the subgroup of patients with persistent symptoms attributed to Lyme borreliosis. Additionally, the current two-tier testing protocol shows a large variance among different manufacturers in these patients.

8 May 2023 in Life
Verified
Journal Article
Open access
PDF file
HHHadewych ter Hofstede
Hadewych ter Hofstede
JHJeroen Haex
Jeroen Haex
MBMichail Belias
Michail Belias
MOMarije Oosting
Marije Oosting
LJLeo A.B. Joosten
Leo A.B. Joosten
FSFoekje Francina Stelma
Foekje Francina Stelma
There is little known about the dynamics within responses to Borrelia spp. upon repeated exposure to tick bites and the development of serological markers over time. Most studies have investigated antibody development in risk populations over a short period of time. Therefore, we aimed to study the dynamics of anti-Borrelia antibodies in forestry service workers over 8 years in association with tick bite exposure. Methods: Blood samples from 106 forestry service workers originally included in the 200 Functional Genomics Project (Radboudumc, Nijmegen, the Netherlands) were followed for 8 years and tested annually for anti-Borrelia antibodies (ELISA and Western blot). IgG seroconversion was related to the number of tick bites in the previous year, which was obtained through annual questionnaires. The hazard ratio for Borrelia IgG seroconversion was calculated using Cox regression survival analysis and a logistic regression model, both adjusting for age, gender and smoking. Results: Borrelia IgG seropositivity in the study population did not vary significantly between years and the average prevalence was 13.4%. Of the 27 subjects that underwent seroconversion during the study period, 22 reconverted from positive to negative. Eleven subjects seroconverted a second time. The total seroconversion rate per year (negative to positive) was 4.5%. Active smoking was associated with IgG seroconversion in the >5 tick bites group (p < 0.05). According to the two models used, the risks of IgG seroconversion in the >5 tick bites group were HR = 2.93 (p = 0.10) and OR = 3.36 (p < 0.0005). Conclusions: Borrelia IgG seroconversion in forestry service workers was significantly related to increasing tick bite exposure in a survival and logistic regression model adjusting for age, gender and smoking.

30 October 2025 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
DHDieneke Hoeve-Bakker
Dieneke Hoeve-Bakker
KKKaren Kerkhof
Karen Kerkhof
ADAlje Pieter Van Dam
Alje Pieter Van Dam
JHJ. W. Hovius
J. W. Hovius
AVA. C. G. Voordouw
A. C. G. Voordouw
DND. W. Notermans
D. W. Notermans
Background Laboratory testing plays an important role in diagnosis and clinical management of Lyme borreliosis (LB). While external quality assessments (EQAs) evaluate the technical quality of laboratory diagnostics, the clinical interpretation of laboratory results often remains unassessed. Although specific guidelines are available, different interpretation can result in variations in clinical diagnosis and subsequent management of LB patients. This study aimed to evaluate variations in interpretating LB laboratory diagnostics in relation to the clinical history of the patient. Methods An EQA was organized for medical microbiological laboratories (MMLs) in the Netherlands using a web-based survey. The survey consisted of twenty LB case descriptions including laboratory findings. Participants were asked to (i) interpret each case according to their protocols (open-ended), and (ii) rate the likelihood of the case being active LB (multiple-choice). Six LB diagnostics experts determined the baseline and scored participants’ answers on a 1–10 scale. Results Of the 50 invited MMLs, 38 (76.0%) completed the survey. The overall mean score was 8.8 (range: 7.2 – 9.8). For the multiple-choice questions, the mean score was 9.6 (range: 8.4 – 10) and for open-ended questions this was 8.0 (range: 5.6 – 9.6). Lower scores were obtained for low-incidence manifestations. Conclusions This EQA showed that interpreting LB laboratory results in relation to the clinical information was good and increased awareness among participants to challenges of LB diagnosis and treatment. Training and education could improve interpretation skills. This EQA might be exemplary for future harmonization efforts for (pan-European) clinical evaluation of LB diagnostics. As a potential future approach, supplementing guidelines with an artificial intelligence-based clinical support system could aid medical microbiologists and physicians in decision making, especially for rare manifestations.